KCP 506
Alternative Names: alpha9/alpha10 nicotinic acetylcholine receptor antagonist - TuHURA Biosciences; KCP-506; nAChR antagonist - TuHURA BiosciencesLatest Information Update: 03 Jul 2025
At a glance
- Originator Kineta
- Developer TuHURA Biosciences
- Class Non-opioid analgesics
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 30 Jun 2025 Kineta has been acquired and merged into TuHURA Biosciences
- 28 Sep 2024 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 28 Jan 2024 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Netherlands